Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of GBP 437.82 million. The enterprise value is 391.88 million.

Market Cap	437.82M
Enterprise Value	391.88M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.18%
Shares Change (QoQ)	+43.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	649.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.84
PB Ratio	2.48
P/TBV Ratio	3.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 98.01, with an EV/FCF ratio of -189.79.

EV / Earnings	-41.43
EV / Sales	1.60
EV / EBITDA	98.01
EV / EBIT	n/a
EV / FCF	-189.79

Financial Position

The company has a current ratio of 3.77, with a Debt / Equity ratio of 0.51.

Current Ratio	3.77
Quick Ratio	2.95
Debt / Equity	0.51
Debt / EBITDA	17.02
Debt / FCF	-43.45
Interest Coverage	-0.41

Financial Efficiency

Return on equity (ROE) is -5.38% and return on invested capital (ROIC) is -0.62%.

Return on Equity (ROE)	-5.38%
Return on Assets (ROA)	-0.52%
Return on Invested Capital (ROIC)	-0.62%
Return on Capital Employed (ROCE)	-1.10%
Revenue Per Employee	587,610
Profits Per Employee	-23,411
Employee Count	404
Asset Turnover	0.69
Inventory Turnover	0.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.36% in the last 52 weeks. The beta is 0.60, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	-22.36%
50-Day Moving Average	0.79
200-Day Moving Average	0.78
Relative Strength Index (RSI)	50.18
Average Volume (20 Days)	68,314

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of GBP 237.39 million and -9.46 million in losses. Loss per share was -0.01.

Revenue	237.39M
Gross Profit	209.12M
Operating Income	-2.87M
Pretax Income	-6.78M
Net Income	-9.46M
EBITDA	2.57M
EBIT	-2.87M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 134.11 million in cash and 89.71 million in debt, giving a net cash position of 44.40 million.

Cash & Cash Equivalents	134.11M
Total Debt	89.71M
Net Cash	44.40M
Net Cash Per Share	n/a
Equity (Book Value)	176.58M
Book Value Per Share	0.26
Working Capital	163.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.43 million and capital expenditures -631,028, giving a free cash flow of -2.06 million.

Operating Cash Flow	-1.43M
Capital Expenditures	-631,028
Free Cash Flow	-2.06M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 88.09%, with operating and profit margins of -1.21% and -3.98%.

Gross Margin	88.09%
Operating Margin	-1.21%
Pretax Margin	-2.86%
Profit Margin	-3.98%
EBITDA Margin	1.08%
EBIT Margin	-1.21%
FCF Margin	n/a

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.18%
Shareholder Yield	-2.18%
Earnings Yield	-2.16%
FCF Yield	-0.47%

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.43
Piotroski F-Score	n/a